Clinical Trial Details
— Status: Completed
Administrative data
| NCT number |
NCT01264055 |
| Other study ID # |
110046 |
| Secondary ID |
11-H-0046 |
| Status |
Completed |
| Phase |
|
| First received |
|
| Last updated |
|
| Start date |
April 26, 2011 |
Study information
| Verified date |
September 29, 2023 |
| Source |
National Institutes of Health Clinical Center (CC) |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Observational
|
Clinical Trial Summary
Background:
- Bronchiectasis is a type of lung condition in which the lungs airways are abnormally
stretched and widened. This stretching and widening makes it difficult for mucus and other
substances to move out of the lungs, encouraging the growth of bacteria and leading to
breathing problems or infection. Bronchiectasis can be caused by genetic disorders or
diseases such as tuberculosis or rheumatoid arthritis. Researchers are interested in
developing better ways to diagnose and treat a lung problem called idiopathic or unexplained
bronchiectasis.
Objectives:
- To better describe the physical characteristics, radiographic patterns, and airway
microbiology of unexplained bronchiectasis and to look for possible genetic links or risk
factors.
Eligibility:
- Individuals at least 18 years of age who have a chronic cough and who have had a CT scan
that has revealed signs of bronchiectasis.
- Current smokers or those who have smoked for at least 10 years, as well as individuals
who have known causes of bronchiectasis or who have had organ transplants, are not
eligible to participate.
Design:
- Participants will have one outpatient clinic visit for evaluation with a physical
examination including detailed body size measurements and medical history and for
collection of blood samples for routine lab tests and genetic analyses and a chest x-ray
if no recent one is available.
- Participants will also have tests of lung function, and measurement of a gas called
nitric oxide in the nose. Participants whose initial tests show abnormal results may
also be asked to have a nasal scrape to collect cell samples and/or a skin sweat test to
measure salt concentrations.
- Participants will also have a sputum specimen collected during the visit and will be
asked to collect two additional early morning sputum samples and a mouth rinse at home
within 2 weeks of the clinic visit, and mail the sample collection materials to the
research team....
Description:
The Genetic Disorders of Mucociliary Clearance Consortium (GDMCC) is comprised of 6
geographically-dispersed clinical research sites designed to study chronic disorders of the
conducting airways associated with bronchiectasis. The first Clinical Center protocol
(06-I-0217) focused on airway diseases with a known genetic etiology: primary ciliary
dyskinesia (PCD), variant cystic fibrosis (vCF), and pseudohypoaldosteronism (PHA). This
second GDMCC protocol will study adult patients with non-CF, idiopathic bronchiectasis, whose
genetic etiologies are not known. Patients will receive the same level of rigorous testing
that has allowed proper diagnosis of patients with PCD, vCF, and PHA.
Idiopathic bronchiectasis is reportedly more common in females with certain asthenic
morphotypes and associated with environmental organisms, such as nontuberculous mycobacterium
(NTM). Gender predilection due to referral bias is unclear. Other susceptibility factors
predisposing to bronchiectasis or acquisition of NTM are also unclear.
The study will attempt to broaden the understanding of this disease by comparing
gender-associated factors and NTM status. A relatively equal number of both females/males and
NTM/non-NTM infected subjects will be accrued. Patients will be stratified by gender and by
the presence/absence of respiratory infection with NTM. Approximately 300 people may be
screened to find 260 eligible subjects since a small number (e.g., 40 patients) may be
diagnosed with PCD, vCF, or other known etiology as an explanation for the bronchiectasis.
This single-visit protocol will use a systematic approach to characterize the clinical,
morphological, radiological, and microbiological phenotypes of idiopathic bronchiectasis.
Physical features, radiographic patterns, and associated lower airway microbial flora will be
assessed. There is no natural history of disease course follow-up component to this protocol.
The standard evaluation includes a quantitative assessment of body morphometrics, functional
assessments of pulmonary physiology, nasal nitric oxide measurement with subsequent detailed
assessment of ciliary structure and motility in selected patients, quantitative
immunoglobulins levels to screen for humoral immune defects, and selected genetic analysis of
candidate alleles, such as CFTR and A1AT.
Genotype/phenotype correlations will be researched and possibly defined. Careful evaluation
and characterization of these phenotypes will guide the genetic characterization of
idiopathic bronchiectasis, and likely lead to an improved diagnostic approach. Identification
of disease causing genes may provide new therapeutic targets.
